1. In Vivo

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Gorsky And Stoffels Go Out On A High

 
• By Eleanor Malone, Brianna Molnar, and Kosh Naran

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

2022 Titans of Phrama
How much did the leaders of the top 20 pharma companies get paid last year? • Source: Shutterstock

Every year, Scrip and In Vivo’s Titans Of Pharma infographic spotlights the executive compensation packages at big pharma, lining CEO and R&D chief remuneration up against other company metrics including sales, net profits, market cap and median employee compensation. We’ve changed the format this year from a static chart to an interactive dashboard and series of visual graphics that enable readers to explore the numbers across multiple years and data points.

The compensation figures provided in our data charts include base salary, bonus and long-term incentives (including equity awards) and are...

More from Leadership

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.